TriSalus Life Sciences, Inc. Common Stock (TLSI) Stock
Fundamentals
Recent news

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TLSI

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TLSI

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TLSI

TriSalus Life Sciences Q2 Earnings Call Highlights
TriSalus Life Sciences Q2 Earnings Call Highlights
TLSI
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TLSI

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TLSI

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TLSI

TriSalus Life Sciences Q2 Earnings Call Highlights
TriSalus Life Sciences Q2 Earnings Call Highlights
TLSI

TriSalus Life Sciences Reports Second Quarter 2026 Results
TriSalus Life Sciences Reports Second Quarter 2026 Results
TLSI

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TLSI

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
TLSI

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TLSI

TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
TLSI

Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
TLSI
About TriSalus Life Sciences, Inc. Common Stock
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Mary T. Szela B.S.N., M.B.A. | CEO, President & Director | 1964 |
| Mr. David B. Patience | Chief Financial Officer | 1986 |
| Dr. Richard B. Marshak M.B.A., VMD | Chief Commercial Officer | 1959 |
| Andrea Marasso | Vice President of Marketing | — |
| Ms. Jennifer L. Stevens J.D. | Chief Regulatory, Quality and Therapeutics Officer | 1962 |
| Dr. Bryan F. Cox Ph.D. | Chief of Research | 1962 |
| Dr. Richard Marshall M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.2 | +24.0 | +1.8 | +4.2 | -16.1 |



